Roundtable: Government Relations

Andrea Ruggiero   ,  Vice President of Community Health,  Open Door Family Medical Centers

Andrea Ruggiero, Vice President of Community Health, Open Door Family Medical Centers

Matthew McLarnon  , Government Relations and Policy Associate,  Capital Health Consulting

Matthew McLarnon, Government Relations and Policy Associate, Capital Health Consulting

Recent Session
Virtual Roundtable: Government Relations, Advocacy for Community Health Centers
March 21, 2019 • RecordingPDF

govt+relations.jpg

Implementing
Volume to Value Initiatives

Speakers:
Andrea Ruggiero, Vice President of Community Health, Open Door Family Medical Centers
Matthew McLarnon, Government Relations and
Policy Associate, Capital Health Consulting

Government policy can be an accelerator of innovation, or a hindrance, impacting progress across the life science and human health landscapes.

Thought leaders will address emerging factors impacting the move from Volume to Value:

-Value Based Models
-Risk Stratification
-Care Coordination
-Patient Advocacy
-Navigation Assistance
-Creative Approaches to Community Engagement

We explore the social determinants of community health, discussing the opportunities and challenges inherent to improving the wellbeing of our communities.

Speakers will cover innovative responses to social challenges, and highlight the need for advocacy by teams and members of the community. Current legislative developments that foster improved community health will also be addressed.

Co-Chairs:
Lisa Wickens-Alteri, President, Capital Health Consulting
Andrew Zebrak, Executive Director, Public Policy,
Therapeutic Areas, and Advocacy, Boehringer Ingelheim


JG Voting 2012.jpg

Past Sessions

Virtual Roundtable: Government Relations Midterm Update,
Outlook for 2019
December 12, 2018 • Recording PDF

Lisa Wickens-Alteri, President, Capital Health Consulting
Matthew McLarnon, Government Relations and Policy Associate
   Capital Health Consulting
Andrew Zebrak, Executive Director, Public Policy,
Therapeutic Areas, and Advocacy, Boehringer Ingelheim

Discussant:
Karl Schmieder, CEO, messagingLAB

Government policy can be an accelerator of innovation, or a hindrance, impacting progress across the life science discovery and development landscape.

After the midterms, what changes in policy may be on the horizon and how will we best navigate them? Experts from our Advisory Board will update us on state and federal life science policy moving forward, anticipating challenges to prepare for and identifying opportunities to support.

Policy Issues for Discussion:

  • Pharmacogenomics: Demonstrating ROI

  • Right to Try for Off Label Medications

  • Behavioral Health/Substance Abuse

  • Pharmacy Distribution of Biosimilars and Biologics

  • Pharmacogenetics and Testing

  • Remote Patient Monitoring: Telehealth and IOT

  • Drug Price Transparency and Controls

  • Improving Patient Awareness, Diagnosis, and Treatment

  • NIH Funding Landscape

  • Incentives and Barriers for R&D

  • Key Legislators Leading the Way

As we move into 2019, how will state and federal budgets change, and who will be impacted most? Where are we heading with the drug pricing debates? Is improved clinical trial access and support a government priority? What is the interplay between HIPAA and research, and how might this evolve in the future? What policies may be on the way that affect patient access to medicines and healthcare?

These topics and more will be addressed for a diverse community of researchers, engineers, data scientists, and those who support them.

Roundtable Co-Chairs:

lisa wickens-alteri.jpg

Lisa Wickens-Alteri is a veteran in the health care community with over 32 years of public and private sector health care delivery experience, both at the State and county level.  Previously, she served as the President of the consulting firm Whiteman Health & Human Services, a Division of Whiteman Osterman & Hanna LLP. Lisa is a Registered Nurse (RN) by background and has displayed her commitment to the health care community by serving for eight years as Deputy Director of the Office of Health Systems Management (OHSM), the policy, regulatory, surveillance and enforcement arm of the New York State Department of Health (NYSDOH). 

Andrew Zebrak.jpg

Andrew Zebrak leads Boehringer Ingelheim’s Public Policy team to engage on federal and state issues, develop strategies to enhance patient access to care, and advance BI objectives. Andrew manages a team of Public Policy colleagues responsible for developing strategies supporting objectives in BI therapeutic areas, including diabetes, cardiovascular disease, COPD, atrial fibrillation, IPF, and oncology. Mr. Zebrak leads BI efforts to collaborate with patient advocacy groups and coalitions on policy issues and key disease states. Prior to his current role, Andrew was Executive Director, Government Affairs & Public Policy at BI where he led the Policy group and oversaw State Government Affairs. He has held a series of positions at BI with increasing responsibility and scope over government affairs and policy.


lisa wickens-alteri.jpg

Making a Difference Through Smart Government Relations
July 25, 2018 • RecordingPDF

Capital Health Consulting, in partnership with the Westchester Biotech Project, invites you to send your questions in prior to the event. This session has been created for you, members of the Westchester Biotech Project.

Lisa Wickens-Alteri, President, Capital Health Consulting
Matthew McLarnon, Government Relations and Policy Associate
   Capital Health Consulting

Through this webinar, the participant will be able to:

  • Describe what Government Relations is (and what it is not);

  • Articulate why it is necessary to educate officials and policy makers on the Life Sciences and the policies and regulations that may carry unintended consequences;

  • Identify why it is necessary to develop strategic partnerships and collaborations;

  • Identify the importance of advocating for a business-friendly environment;

  • Identify grant and economic development opportunities to the benefit of your organization and our communities.

  • And, answer your questions about New York State Government, legislative, executive and regulatory bodies.

Since the establishment of the New York State Life Sciences Initiative, in 2016, science and technology has found new life in New York. Over 47 companies have launched in New York State over the last three decades, placing NY in the #2 spot in the nation for funding biotech and life science research and development. Even with the positive influx of investment and the establishment of science and technology as a public authority in New York, the industry is still confronted by governmental barriers and bureaucratic policy.

Speakers:

Lisa Wickens-Alteri is a veteran in the health care community with over 32 years of public and private sector health care delivery experience, both at the State and county level.  Previously, she served as the President of the consulting firm Whiteman Health & Human Services, a Division of Whiteman Osterman & Hanna LLP. Lisa is a Registered Nurse (RN) by background and has displayed her commitment to the health care community by serving for eight years as Deputy Director of the Office of Health Systems Management (OHSM), the policy, regulatory, surveillance and enforcement arm of the New York State Department of Health (NYSDOH). 

Matthew McLarnon serves as the Government Relations and Policy Associate for Capital Health Consulting LLC. He comes to Capital Health Consulting LLC from the New York State Assembly’s Department of Communication and Information Services. He specializes in researching and monitoring all forms of policy and government initiatives whether it be legislative or regulatory activity. With the Assembly he tracked legislation, researched outreach programs, and managed the production of members’ communication materials, including press releases, columns and mailers. In addition, Matthew has assisted on several political campaigns from the North Country to Long Island with the Democratic Assembly Campaign Committee.

Capital Health Consulting (CHC) is a woman-owned and operated business, serving health care clients with the expertise cultivated by careers in government, health and policy. They have a broad understanding of the specialties and nuances of healthcare and can assist clients in creating cutting edge projects commensurate with the expectations of a changing healthcare industry. Their strategy frequently includes educating providers on current policy discussions and future expectations in order to engage elected officials regarding rule or rate-making decisions. 

WBP Top border.png